| Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade L Rivoltini, C Camisaschi, G Fucà, B Paolini, B Vergani, V Beretta, ... Scientific Reports 14 (1), 3379, 2024 | 1 | 2024 |
| 114P Effects of chemotherapy on TREG lymphocytes in early breast cancer S Cresta, A Tessari, A Aiello, B Paolini, A Martinetti, L Mariani, S Damian, ... ESMO Open 9, 2024 | | 2024 |
| Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical … D Robbrecht, JJ Grob, O Bechter, M Simonelli, B Doger, I Borbath, ... Clinical and translational science 17 (2), e13736, 2024 | | 2024 |
| Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà 2, Biagio Paolini 4, Barbara Vergani 5, Valeria Beretta, Silvia Damian 2, Matteo Duca 2, Sara Cresta 2, Michele Magni 2 … M Di Nicola Scientific Reports 14, 3379, 2024 | | 2024 |
| A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies D Mahalingam, CC Lin, PL Bedard, M Di Nicola, Z Wainberg, P LoRusso, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract A020: Reversing triple negative breast cancer stem cells by disrupting the Notch signaling pathway via BCL6 targeting F De Santis, F Putti, G Bravin, C Portulano, F Zonca, L Castagnoli, ... Molecular Cancer Therapeutics 22 (12_Supplement), A020-A020, 2023 | | 2023 |
| Abstract B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies D Mahalingam, CC Lin, PL Bedard, MD Nicola, Z Wainberg, P LoRusso, ... Molecular Cancer Therapeutics 22 (12_Supplement), B114-B114, 2023 | | 2023 |
| A phase II study of tinostamustine in patients (pts) with advanced solid tumours. A Tinker, JF Strauss, R Schneider, R Chugh, G Curigliano, MA Di Nicola, ... Journal of Clinical Oncology 41 (16_suppl), 3021-3021, 2023 | | 2023 |
| 77P BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: A retrospective analysis L Provenzano, C Giani, L Mazzeo, S Pessina, D Sorrentino, A Castano, ... ESMO Open 8 (1), 2023 | | 2023 |
| Extracellular matrix drives high-grade breast cancer immune suppression down-modulating PD-1 on Treg cells via the IL-23/SATB1 axis G Talarico, M Lecchi, M Costanza, C Chiodoni, V Cappelletti, P Verderio, ... Cancer Research 83 (7_Supplement), 3637-3637, 2023 | 1 | 2023 |
| Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials JL Perez-Gracia, N Penel, E Calvo, A Awada, HT Arkenau, T Amaral, ... Annals of Oncology 34 (1), 70-77, 2023 | 11 | 2023 |
| 774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors C Le Tourneau, S Piha-Paul, H Prenen, B Delafontaine, D Pinato, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy M Bellone, M Bregni, V Bronte, S Ugel, PF Ferrucci, M Di Nicola, P Nisticò, ... Cancer Immunology, Immunotherapy, 1-10, 2022 | | 2022 |
| CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors … M Schenker, M Burotto, M Richardet, T Ciuleanu, A Goncalves, N Steeghs, ... Cancer Research 82 (12), 2022 | 13 | 2022 |
| Abstract CT022: CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or … M Schenker, M Burotto, M Richardet, T Ciuleanu, A Goncalves, N Steeghs, ... Cancer Research 82 (12_Supplement), CT022-CT022, 2022 | 8 | 2022 |
| BCL6 and the Notch pathway: A signaling axis leading to a novel druggable biotarget in triple negative breast cancer F De Santis, SL Romero-Cordoba, L Castagnoli, T Volpari, S Faraci, ... Cellular Oncology 45 (2), 257-274, 2022 | 9 | 2022 |
| Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy? M Ambrosini, G Fucà, M Duca, S Damian, F De Santis, F Corti, S Cresta, ... Critical Reviews in Oncology/Hematology 169, 103532, 2022 | 8 | 2022 |
| 520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients … D Robbrecht, G Jean-Jacques, O Bechter, A Santoro, B Doger, I Borbath, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 3 | 2021 |
| 838P Rituximab and non-pegylated liposomial doxorubincin (R-NPLD) treatment in patients 80 years of age or older affected by diffuse large B-cell lymphoma (DLBCL): A 2020 … C Cantò, E Pennese, M Di Nicola, G Ricciuti, F Restuccia, S Luciani, ... Annals of Oncology 32, S777-S778, 2021 | | 2021 |
| Nanobiotechnology and immunotherapy: Two powerful and cooperative allies against cancer F Mainini, F De Santis, G Fucà, M Di Nicola, L Rivoltini, M Eccles Cancers 13 (15), 3765, 2021 | 7 | 2021 |
